Evidence map›Paper›PMID 26230936›Full record

ArticlePloS one2015

Effect of Osmotic Pressure on the Stability of Whole Inactivated Influenza Vaccine for Coating on Microneedles.

Hyo-Jick Choi, Jae-Min Song, Brian J Bondy, Richard W Compans, Sang-Moo Kang, Mark R Prausnitz

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Thermostabilization of virusesBiomaterials science · 2020
    Article
  14. Review
  15. Microneedle Coating Methods: A Review with a Perspective.The Journal of pharmacology and experimental therapeutics · 2019
    Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Hyo-Jick ChoiSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America; Department of Chemical and Materials Engineering, University of Alberta, Edmonton, Alberta, Canada.
Jae-Min SongDepartment of Global Medical Science, Sungshin Women's University, Seoul, Korea.
Brian J BondySchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Richard W CompansDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, Georgia, United States of America.
Sang-Moo KangCenter for Inflammation, Immunity, & Infection and Department of Biology, Georgia State University, Atlanta, Georgia, United States of America.
Mark R PrausnitzSchool of Chemical and Biomolecular Engineering, Georgia Institute of Technology, Atlanta, Georgia, United States of America.
Georgia Institute of Technology · USEmory University · USGeorgia State University · USSungshin Women's University · KR

Funding

Influenza vaccination using a microneedle patchU01EB012495 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2010 to 2015
$9.6M
Influenza vaccines inducing broadly cross protective immunityR01AI093772 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2011 to 2020
$4.2M
VLP Vaccine TechnologyR01AI105170 · NIAID · GEORGIA STATE UNIVERSITY · PI KANG, SANG-MOO · 2013 to 2017
$3.7M
Microneedle-based immunization against pandemic influenzaR01EB006369 · NIBIB · GEORGIA INSTITUTE OF TECHNOLOGY · PI PRAUSNITZ, MARK R. · 2007 to 2011
$3.6M
NIAID NIH HHS AI0680003NIAID NIH HHS AI093772NIAID NIH HHS AI105170NIAID NIH HHS R01 AI093772NIAID NIH HHS R01 AI105170NIBIB NIH HHS EB006369NIBIB NIH HHS EB012495NIBIB NIH HHS R01 EB006369NIBIB NIH HHS U01 EB012495
6 · The paper itself

Abstract

Enveloped virus vaccines can be damaged by high osmotic strength solutions, such as those used to protect the vaccine antigen during drying, which contain high concentrations of sugars. We therefore studied shrinkage and activity loss of whole inactivated influenza virus in hyperosmotic solutions and used those findings to improve vaccine coating of microneedle patches for influenza vaccination. Using stopped-flow light scattering analysis, we found that the virus underwent an initial shrinkage on the order of 10% by volume within 5 s upon exposure to a hyperosmotic stress difference of 217 milliosmolarity. During this shrinkage, the virus envelope had very low osmotic water permeability (1 - 6×10-4 cm s-1) and high Arrhenius activation energy (Ea = 15.0 kcal mol-1), indicating that the water molecules diffused through the viral lipid membranes. After a quasi-stable state of approximately 20 s to 2 min, depending on the species and hypertonic osmotic strength difference of disaccharides, there was a second phase of viral shrinkage. At the highest osmotic strengths, this led to an undulating light scattering profile that appeared to be related to perturbation of the viral envelope resulting in loss of virus activity, as determined by in vitro hemagglutination measurements and in vivo immunogenicity studies in mice. Addition of carboxymethyl cellulose effectively prevented vaccine activity loss in vitro and in vivo, believed to be due to increasing the viscosity of concentrated sugar solution and thereby reducing osmotic stress during coating of microneedles. These results suggest that hyperosmotic solutions can cause biphasic shrinkage of whole inactivated influenza virus which can damage vaccine activity at high osmotic strength and that addition of a viscosity enhancer to the vaccine coating solution can prevent osmotically driven damage and thereby enable preparation of stable microneedle coating formulations for vaccination.

Indexed as

Influenza VaccinesNeedlesVaccine PotencyAnimalsDogsHemagglutination TestsInfluenza A Virus, H1N1 SubtypeMadin Darby Canine Kidney CellsMiceOsmotic PressureViscosityInfluenza Vaccines

Identifiers

PMID26230936
PMCPMC4521748
OpenAlexW1866599711

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.